Paper Details

  1. Home
  2. Paper Details

Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.

Author: ChaoYee, HouMing-Chih, HuangYi-Hsiang, LanKeng-Hsin, LeeI-Cheng, LiChung-Pin, LinHan-Chieh, SuChien-Wei

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study looked at the risk of kidney problems in patients with hepatitis B who were receiving chemotherapy and taking either tenofovir or entecavir to prevent the virus from spreading. About one-third of the patients had some kidney problems, but there was no difference in risk between the two drugs.
Paper Details　
Original Abstract of the Article :
The risk of renal events in HBsAg-positive cancer patients receiving tenofovir disoproxil fumarate (TDF) or entecavir (ETV) antiviral prophylaxis during chemotherapy has not been evaluated. This study aimed to evaluate the renal safety of TDF and ETV during chemotherapy. Consecutive, 219 HBsAg-posit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12984

データ提供：米国国立医学図書館（NLM）

A Balancing Act: Renal Safety in HBsAg-Positive Cancer Patients

This study delves into the complex landscape of antiviral prophylaxis for HBsAg-positive cancer patients receiving chemotherapy. It investigates the renal safety of two commonly used antiviral drugs, tenofovir disoproxil fumarate (TDF) and entecavir (ETV), examining their potential impact on kidney function.

Navigating the Shifting Sands of Renal Risk: A Balanced Perspective

The research reveals that while both TDF and ETV can pose a risk of renal events, there was no significant difference in the incidence of these events between the two drugs. The study provides valuable information for clinicians, highlighting the importance of careful monitoring of kidney function in patients receiving either drug.

A Journey Through the Oasis of Informed Decision-Making: A Guide for Healthcare Professionals

The study underscores the importance of individualized care for HBsAg-positive cancer patients receiving antiviral prophylaxis. It emphasizes the need for meticulous monitoring of kidney function, ensuring optimal management and reducing the risk of renal complications.

Dr.Camel's Conclusion

This research provides a valuable perspective on the renal safety of TDF and ETV in HBsAg-positive cancer patients receiving chemotherapy. The findings highlight the importance of careful monitoring of kidney function and individualized care for these patients, allowing clinicians to navigate the delicate balance of antiviral prophylaxis and renal safety.

Date :
  1. Date Completed 2019-10-10
  2. Date Revised 2019-10-10
Further Info :

Pubmed ID

30125436

DOI: Digital Object Identifier

10.1111/jvh.12984

Related Literature

Article Analysis
・Side Effects of entecavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.